{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-116493","form_type":"8-K","ticker":"MIST","cik":"0001408443","company_name":"Milestone Pharmaceuticals Inc.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.366867+00:00","generated_at":"2026-05-30T01:47:15.252059+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Milestone reports Q3 net loss of $9.4M; PDUFA for CARDAMYST set for March 27, 2025","bullets":["PDUFA target date for CARDAMYST (etripamil) in PSVT is March 27, 2025.","China Phase 3 met primary endpoint: 40.5% conversion vs 15.9% placebo within 30 min (HR=3.00, p<0.001).","Phase 3 trial in AFib-RVR expected to start H1 2025 with repeat-dose 70 mg regimen.","Cash, equivalents and short-term investments $76.4M at Sep 30, 2024, up from $66.0M at Dec 31, 2023.","Net loss narrowed to $9.4M in Q3 2024 vs $15.1M in Q3 2023; R&D expense $4.0M vs $6.7M."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-116493","json":"https://secwatch.observer/filing/0001104659-24-116493.json","markdown":"https://secwatch.observer/filing/0001104659-24-116493.md","text":"https://secwatch.observer/filing/0001104659-24-116493.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1408443/000110465924116493/0001104659-24-116493-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1408443/000110465924116493/tm2428099d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T01:47:15.252059+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}